ADIPOQ and type 2 diabetes mellitus: The shift toward a proinflammatory EAT secretome has also been observed in type 2 diabetes mellitus (T2DM), with a reduction in adiponectin and increase in expression of MCP-1 and CD68+ cells compared with nondiabetic counterparts (44).